Get the Stockscreener App
1.75
10.26%
-0.20
Pre-market:
1.82
0.07
+4.00%
Palisade Bio Inc stock is traded at $1.75, with a volume of 6.93M.
It is down -10.26% in the last 24 hours and down -3.31% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.95
Open:
$1.94
24h Volume:
6.93M
Relative Volume:
1.38
Market Cap:
$261.11M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.1251
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
-7.89%
1M Performance:
-3.31%
6M Performance:
+133.33%
1Y Performance:
-0.57%
1-Day Range:
$1.75
$1.94
1-Week Range:
$1.75
$2.03
52-Week Range:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.75 | 290.95M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio (PALI) Price Target Increased by 12.86% to 13.43 - Nasdaq
Palisade Bio director Williams buys $9,400 in shares - Investing.com
Sentiment Watch: Can Palisade Bio Inc beat the S P 500July 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Short Covering: Is Palisade Bio Inc stock a dividend growth opportunity2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - moha.gov.vn
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
PALI: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
B. Riley Initiates Palisade Bio at Buy With $7 Price Target - marketscreener.com
B.Riley initiates coverage on Palisade Bio stock with Buy rating By Investing.com - Investing.com Nigeria
B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com Nigeria
How Palisade Bio Inc. (7NS0) stock reacts to Fed tighteningShort Setup & Consistent Profit Trading Strategies - Улправда
Can Palisade Bio Inc. stock deliver consistent earnings growthTrade Risk Report & Expert Approved Momentum Ideas - Улправда
What is the fair value of Palisade Bio Inc. stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - Улправда
Crohn’s & Colitis Foundation invests up to $500,000 in Palisade Bio By Investing.com - Investing.com Nigeria
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - Улправда
Exit Recap: Will Palisade Bio Inc stock attract more institutional investors2025 AllTime Highs & High Conviction Buy Zone Alerts - Bộ Nội Vụ
Palisade Bio Announces Strategic Investment from Crohn's & Colitis Foundation to Support Development of PALI-2108 for Ulcerative Colitis and Crohn's Disease - Quiver Quantitative
Crohn’s & Colitis Foundation backs new gut-targeted drug for severe IBD - Stock Titan
Will Palisade Bio Inc. stock benefit from sector rotationStability vs Neutral Overview & HOKA buying tips before checkout - ulpravda.ru
Palisade Bio, Inc. (NASDAQ:PALI) Receives $20.50 Average Price Target from Analysts - Defense World
Wall Street Zen Upgrades Palisade Bio (NASDAQ:PALI) to "Hold" - MarketBeat
Risk Report: What is the fair value of Palisade Bio Inc stock now2025 Major Catalysts & Intraday High Probability Setup Alerts - moha.gov.vn
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Palisade Bio (NASDAQ:PALI) Stock Rating Upgraded by Clear Str - MarketBeat
Piper Sandler Initiates Coverage on Palisade Bio (NASDAQ:PALI) - Defense World
9,119,152 Common Stock of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Stock Options of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Warrants of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 - Investing.com Nigeria
Palisade Bio Says Japan Grants Patent for Composition of PALI-2108 - MarketScreener
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 By Investing.com - Investing.com South Africa
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
Palisade Bio (NASDAQ:PALI) Upgraded at Piper Sandler - MarketBeat
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 - The Manila Times
Palisade Bio stock initiated with Buy rating at Clear Street on IBD drug potential - Investing.com
Palisade Bio Appoints New VP to Drive Further Growth - StocksToTrade
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - Benzinga
PALI’s Strategic Move: What’s Next? - timothysykes.com
Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug By Investing.com - Investing.com Nigeria
Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug - Investing.com
Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results - Finviz
10 Stocks Lighting Up Market Ahead of Christmas - Insider Monkey
Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
Aug Summary: Is Palisade Bio Inc stock ready for breakout2025 Macro Impact & AI Enhanced Market Trend Forecasts - moha.gov.vn
Published on: 2025-12-21 10:03:36 - Улправда
Why analysts remain bullish on Palisade Bio Inc. stock2025 Top Gainers & High Accuracy Investment Signals - Улправда
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
1.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):